THERAPEUTIC AND ANTILIPOPEROXIDANT EFFECTS OF SILYBIN-PHOSPHATIDYLCHOLINE COMPLEX IN CHRONIC LIVER DISEASE: PRELIMINARY RESULTS

Abstract Eight patients (two men and six women; mean age, 54.6 + 5 years) with viral chronic active hepatitis were treated with silipide (IdB1016), a new silybin-phosphatidylcholine complex, for 2 months. After treatment with IdB1016, serum malondialdehyde levels decreased by 36%, and the quantitative liver function evaluation, as expressed by galactose elimination capacity, increased by 15%. A statistically significant reduction ( P